Good luck Nomis - I look forward to your report after the event.
Benchmark, apart from exceptions like Nomis, choices of treatment could be summarised as:
HIFU v active surveillance - for men with very early, low grade cancer, T1
RP v RT (with or without HT) v low dose brachytherapy - medium risk cancer, G7 & G8, T2
RP v RT/HT v high dose brachytherapy v high dose brachy + RT/HT - high risk, G9 or G10, T3
Up front chemo, HT, apalutimide, enzalutimide, etc - advanced / metastatic cancer
Cryotherapy / green light laser therapy / proton beam therapy - gamblers and those who would not be distressed or bankrupted by a recurrence.
These are a little simplistic - for example, some men diagnosed with T3 are now offered pre-emptive chemo when they never would have been 5 years ago. And some men with T3b/T4 are offered radical treatments even though they are incurable - doctors want to know whether removing the gland slows down the progression. But HIFU is not generally an option to be compared & contrasted with RP / RT - the outcome is significantly poorer in terms of recurrence.